Table 3.
Results of Analysis of Recurrent Events.
| 4-weekly | 12-weekly | |
|---|---|---|
| Median (maximum) Follow-Up (Years) | ||
| Alive at Last Follow-Up | 1.96 (3.70) | 1.96 (3.62) |
| Deceased at Last Follow-Up | 1.38 (3.45) | 1.23 (3.49) |
| All SSE | 73 | 100 |
| Radiotherapy to bone | 54 | 67 |
| Pathological fracture | 5 | 10 |
| Surgery to bone | 3 | 8 |
| Spinal cord compression | 3 | 8 |
| Hypercalcaemia | 8 | 7 |
| Number of SSE Per Patient | ||
| N (%) ≥ 1 | 44 (33.9) | 44 (33.1) |
| 0 1 2 3 4 5 6 7 8 |
89 (66.9) 29 (21.8) 7 (5.3) 5 (3.8) 1 (0.8) 1 (0.8) 1 (0.8) 0 (0) 0 (0) |
86 (66.2) 21 (16.2) 10 (7.7) 6 (4.6) 3 (2.3) 0 (0) 1 (0.8) 1 (0.8) 2 (1.5) |
| Mean (sd) Events per Patient | Mean (sd) Events per Patient | |
| All | 0.55 (1.03) | 0.77 (1.52) |
| BTA Naïve | 0.50 (1.02) | 0.84 (1.71) |
| Prior exposure | 0.59 (1.04) | 0.67 (1.21) |
| Denosumab | 0.52 (0.94) | 0.85 (1.48) |
| Pamidronate | 0.48 (0.65) | 0.89 (2.06) |
| Zoledronate | 0.68 (1.42) | 0.50 (1.02) |
| Breast cancer | 0.58 (1.07) | 0.62 (1.38) |
| Prostate cancer | 0.50 (0.96) | 1.00 (1.71) |
| Mean (sd) per patient | Mean (sd) per patient | |
| Skeletal Morbidity Rates (SSE / year) | 0.41 (1.20) | 0.45 (0.86) |